Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
- Resource Type
- Source
- Blood. 140:2411-2413
- Subject
Immunology Cell Biology Hematology Biochemistry - Language
- ISSN
- 1528-0020
0006-4971